Generic Name: dapagliflozin
Brand Name: Forxiga
Manufacturer: AstraZeneca Canada Inc.
Indications: Heart failure with reduced ejection fraction
Manufacturer Requested Reimbursement Criteria1: For the treatment of heart failure (HF) with reducedejection fraction in patients with New York Heart Association (NYHA) class II,III, or IV HF to reduce the risk of cardiovascular (CV) death, hospitalizationfor heart failure and urgent heart failure visit, and to improve heart failuresymptoms, if the following clinical criteria are met: Reduced left ventricular ejection fraction (LVEF) ( 40%). As an adjunct to standard of care therapy, such as astable dose of an angiotensin-converting enzyme inhibitor (ACEi) or anangiotensin II receptor antagonist (ARB), a beta blocker and an aldosteroneantagonist (if tolerable).
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||March 03, 2020|
|Call for patient input closed||April 22, 2020|
- Patient input submission received from Cardiac Health Foundation of Canada, Heart Failure Support Group of Manitoba and HeartLife Foundation
|Submission received||March 31, 2020|
|Submission accepted||April 27, 2020|
- Submission was not accepted for review on 15 Apr 2020
- Revised category 1 requirements received on 27 Apr 2020
|Review initiated||April 28, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||July 29, 2020|
|Deadline for sponsors comments||August 10, 2020|
|CADTH responses on draft review report(s) provided to sponsor||September 03, 2020|
|Expert committee meeting (initial)||September 16, 2020|
|Draft recommendation issued||September 28, 2020|
September 30, 2020